Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,604 public trials 495 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 29 locations
View Trial Details
Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • O Neal Comprehensive Cancer Center at UAB Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
View all 69 locations
View Trial Details
Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • UCSF Fresno Clovis, California, United States
  • City of Hope Duarte Duarte, California, United States
View all 270 locations
View Trial Details
Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tufts Medical Center (Data Collection Only) Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Emory University Atlanta, Georgia, United States
  • Nebraska Cancer Specialists Omaha, Nebraska, United States
View all 29 locations
View Trial Details
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • LKH Leoben Leoben, Austria
  • Krankenhaus der barmherzigen Schwestern Vienna, Austria
  • UZ Antwerpen Edegem, Belgium
  • Ziekenhuis Oost-Limburg Genk, Belgium
View all 90 locations
View Trial Details
Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
  • CHU Lyon Sud - Service Hématologie Pierre-Bénite, France
  • IUCT Oncopole Toulouse, France
View all 16 locations
View Trial Details
Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Royal Adelaide Hospital;Haematology Clinical Trials Unit Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Melbourne, Victoria, Australia
View all 14 locations
View Trial Details

Related conditions